Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11041499 | 0.77 | TGFBR1 (0.34) | — | |
| SCHEMBL9111266 | 0.77 | MGAM (0.31) | — | |
| SCHEMBL722745 | 0.76 | OR51E2 (0.39) | OR51E2 | |
| SCHEMBL28406761 | 0.75 | LMNA (0.33) | TDP1 | |
| SCHEMBL8909433 | 0.75 | CYP2C19 (0.34) | — | |
| SCHEMBL30119760 | 0.75 | THRB (0.31) | — | |
| SCHEMBL9491117 | 0.74 | OR51E2 (0.32) | OR51E2 | |
| Acetone SCHEMBL11165964 | 0.74 | TSHR (0.32) | OR51E2TDP1 | |
| SCHEMBL27530396 | 0.72 | USP2 (0.32) | OR51E2TDP1 | |
| SCHEMBL7155092 | 0.72 | CES2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260033491-A1 | FUNGAL SPORE FORMULATIONS INCLUDING CARRIER FLUIDS | BAYER AG (DE) | 2026-02-05 | — | — | US | claimed |
| EP-3443034-B1 | COMPOSITION | DELTA OF SWEDEN AB (SE) | 2024-04-10 | — | — | EP | claimed |
| US-20220007643-A1 | NOVEL CARRIER FLUIDS FOR LIQUID FUNGAL SPORE FORMULATIONS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2022-01-13 | — | — | US | claimed |
| EP-3823448-A1 | NOVEL CARRIER FLUIDS FOR LIQUID FUNGAL SPORE FORMULATIONS | Bayer Aktiengesellschaft (DE) | 2021-05-26 | — | — | EP | claimed |
| CN-108884250-B | Compositions and methods for making sulfone polymer membranes | 索尔维特殊聚合物意大利有限公司 | 2021-03-23 | — | — | CN | claimed |
| EP-3430076-B1 | COMPOSITION AND METHOD FOR MANUFACTURING SULFONE POLYMER MEMBRANE | SOLVAY SPECIALTY POLYMERS IT (IT) | 2020-07-15 | — | — | EP | claimed |
| WO-2020016070-A1 | NOVEL CARRIER FLUIDS FOR LIQUID FUNGAL SPORE FORMULATIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-01-23 | — | — | WO | claimed |
| EP-1100479-B2 | MEDICINAL PRODUCTS WITH RETARDED PHARMACOLOGICAL ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF | SCHIERHOLZ JÖRG DR DR (DE) | 2016-12-07 | — | — | EP | claimed |
| EP-1693055-B1 | Gelatin hard capsule having enhanced film strength | SUHEUNG CAPSULE CO LTD (KR) | 2008-09-10 | — | — | EP | claimed |
| EP-1100479-B1 | MEDICINAL PRODUCTS WITH RETARDED PHARMACOLOGICAL ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF | SCHIERHOLZ JOERG DR DR (DE) | 2006-01-11 | — | — | EP | claimed |
| US-20030133829-A1 | Process for inactivating pathogens in a biological material | BAXTER HEALTHCARE CORPORATION | 2003-07-17 | — | — | US | claimed |
| WO-2003053477-A1 | PROCESS FOR INACTIVATING PATHOGENS IN A BIOLOGICAL SOLUTION | BAXTER INTERNATIONAL INC. (US) | 2003-07-03 | — | — | WO | claimed |
| EP-0070166-B1 | CONTAINER CLOSURE HAVING A LINER | JAPAN CROWN CORK CO. LTD. (JP) | 1985-08-28 | — | — | EP | claimed |
| US-20260033491-A1 | FUNGAL SPORE FORMULATIONS INCLUDING CARRIER FLUIDS | BAYER AG (DE) | 2026-02-05 | — | — | US | disclosed |
| US-20250380734-A1 | AEROSOL GENERATING SUBSTRATE, AEROSOL GENERATING PRODUCT, AND AEROSOL GENERATING DEVICE | SMOORE INTERNATIONAL HOLDINGS LTD (KY) | 2025-12-18 | — | — | US | disclosed |
| EP-4656065-A1 | AEROSOL GENERATION SUBSTRATE, AEROSOL GENERATION PRODUCT, AND AEROSOL GENERATION DEVICE | Smoore International Holdings Limited (KY) | 2025-12-03 | — | — | EP | disclosed |
| EP-0660697-A1 | MOISTURIZING LIPSTICK COMPOSITIONS. | PROCTER & GAMBLE (US) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994006401-A1 | MOISTURIZING LIPSTICK COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-31 | — | — | WO | disclosed |
| EP-0398340-B1 | Ceramide derivatives and their use as inhibitors in the sphingolipid synthesis | THERA PATENT VERWALTUNGS GMBH (DE) | 1994-01-05 | — | — | EP | disclosed |
| EP-0398340-A1 | Ceramide derivatives and their use as inhibitors in the sphingolipid synthesis | THERA - Patent Verwaltungs-GmbH (DE) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220007643-A1 | NOVEL CARRIER FLUIDS FOR LIQUID FUNGAL SPORE FORMULATIONS | GET3, ERG28, SUCLG1 | OR51E2 1631/4885TDP1 3835/4885 |
| US-20260033491-A1 | FUNGAL SPORE FORMULATIONS INCLUDING CARRIER FLUIDS | ERG28, CERT1, MGLL | OR51E2 3053/4885TDP1 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.